Company Description

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States.

The company's lead product candidates include TTI-101, which is in Phase 2 clinical development for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage.

Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

Tvardi Therapeutics, Inc.

Country	United States
Founded	2017
Industry	Biotechnology
Sector	Healthcare
Employees	12
CEO	Imran Alibhai

Contact Details

Address: 3 Sugar Creek Center Boulevard, Suite 525 Sugar Land, Texas 77478 United States
Phone	713 489 8654
Website	tvarditherapeutics.com

Stock Details

Ticker Symbol	TVRD
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001742947
CUSIP Number	140755307
ISIN Number	US1407553072

Key Executives

Name	Position
Dr. Imran Alibhai Ph.D.	Chief Executive Officer and Director
Wallace Hall	Founder, President and Director
Dan Conn J.D., M.B.A.	Chief Financial Officer
Dr. John Kauh M.D.	Chief Medical Officer
David J. Tweardy M.D.	Co-Founder and Scientific Advisory Board Member
Dr. Ronald A. DePinho M.D.	Co-Founder and Chairman of Scientific Advisory Board
Dr. Michael T. Lewis Ph.D.	Co-Founder and Scientific Advisory Board Member
Dr. Jeffrey Larson DABT, Ph.D.	Senior Vice President of Research & Development
Stephen O'Brien CPA	Vice President of Finance and Corporate Controller
Dr. Yixin Chen Ph.D.	Vice President of CMC